Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial

NCT00992706 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT00992706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Local Antiperspirant for Prevention of Palmar-Plantar Erythrodysesthesia (PPE) in Patients Treated With Pegylated Liposomal Doxorubicin: A Randomized, Multicenter, Double Blinded, Phase III Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2009
Completion date
June 30, 2012
Enrollment
91 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, palmar-plantar erythrodysesthesia